Treatment of bronchial secretion disorders, particularly in acute bronchitis: acute bronchitis and acute episode of chronic bronchopneumonia

Adult and child over 7 years of age, 600 mg per day in 3 doses, ie 1 tablet 3 times a day,
Child 2 to 7 years: 400 mg, per day, in 2 doses, that is 1 tablet twice a day.
The duration of the treatment will not exceed 8 to 10 days without medical notice.

Oral use.

Dissolve the tablet in half a glass of water.

MUCOLYTICS

(R: Respiratory system)

Acetylcysteine ​​is a mucolytic mucoformer. It exerts its action on the gel phase of the mucus, presumably by breaking the bridges, disulfides of the glycoproteins, and thus promotes the expectoration.
Not applicable.

· History of hypersensitivity to any of the constituents

· Infant (under 2 years of age) (see Warnings and Precautions for Use).
Warnings

The productive coughs, which represent a fundamental element of broncho-pulmonary defense, must be respected.

The association of mucomodifiers, bronchodilators with antitussives and / or substances, drying (atropinic) secretions is irrational

Mucolytics can induce bronchial overcrowding in infants. Indeed, its capacity for draining bronchial mucus is limited, due to the physiological peculiarities of its respiratory tree. They should therefore not be used in infants (see section Contraindications and adverse effects)

Treatment should be re-evaluated in the event of persistence or aggravation of symptoms or pathology.

This medicinal product contains sorbitol and is not recommended for use in patients with fructose intolerance (rare hereditary disease)

Precautions for use

Caution is recommended in patients with ulcers, gastroduodenal

This medicine contains sodium, which contains 0.6 g sodium per tablet, effervescent. To be taken into account in patients following a strict diet.

Not applicable.

Not applicable.

Not applicable.

Pregnancy

Studies in animals have not shown any teratogenic effect. In the absence of teratogenic effect in animals, a malformative effect in the human species is not expected. Indeed, to date, the substances responsible for malformations in the human species have been found to be teratogenic in animals in well-conducted studies of two species

In the clinic, no particular malformative or fetotoxic effect has appeared to date.
However, monitoring of pregnancies exposed to acetylcysteine ​​is insufficient to rule out any risk.

Therefore, the use of acetylcysteine ​​should only be considered during pregnancy if necessary.


There is no data concerning the passage of acetylcysteine ​​in breast milk.

However, due to its low toxicity, the potential risks to the child appear negligible when treated with this medication, therefore breastfeeding is possible.

· Risk of bronchial over-crowding, especially in the infant and in some patients who are incapable of expectoration, effective (see sections Contraindications and Warnings and Precautions). >

Allergic skin reactions such as pruritus, erythematous rash, urticaria and angioedema

· Possibility of phenomena, intestinal digestive (gastralgia, nausea, diarrhea).

It is then advisable to reduce the dose.

Treatment of bronchial secretion disorders, particularly in acute bronchitis: acute bronchitis and acute episode of chronic bronchopneumonia